Ontology highlight
ABSTRACT: Background
Epidermal growth factor receptor (EGFR) is a well-known target for cancer treatment. However, the authorized anti-EGFR monoclonal antibodies generally cause several toxic effects, especially severe cutaneous toxicities as well as infusion reactions, and the clinical indications are limited. Here we developed Ametumumab, a fully human recombinant anti-EGFR monoclonal antibody.Objectives
To assess the safety, tolerability, pharmacokinetics (PK), and immunogenicity of Ametumumab.Design
A first-in-human phase Ia dose escalation study of Ametumumab in patients with advanced solid malignancies.Methods
An open-label, first-in-human dose escalation study was done in 22 patients with advanced malignancies who received six ascending dosages ranging from 75
SUBMITTER: Li D
PROVIDER: S-EPMC10071157 | biostudies-literature | 2023
REPOSITORIES: biostudies-literature